文献速递妇科肿瘤

晚期复发性卵巢癌接受聚腺苷二磷酸核糖聚合酶抑制剂治疗后继发性骨髓增生异常综合征和急性髓系白血病的风险:英格兰回顾性队列研究

Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England.
PubMed 文献 · Eur J Cancer · 2025-04-25

该回顾性队列研究纳入英格兰11,531例晚期复发性卵巢癌患者,计算完成一线化疗后5年内继发性骨髓增生异常综合征(MDS)/急性髓系白血病(AML)的发病率。结果显示,化疗联合PARPi维持治疗组绝对风险为0.3%(5/1529),化疗 alone 组为0.1%(10/10,002);相对风险为2.97(95%CI 1.02,8.68,p=0.046)。作者认为相对风险虽升高,但两组绝对风险均较低,且低于临床试验Meta分析报告的0.73%。

要点

  • 化疗联合PARPi维持治疗组MDS/AML绝对风险0.3%,化疗 alone 组0.1%。
  • PARPi维持治疗相比化疗 alone 的相对风险为2.97(95%CI 1.02,8.68,p=0.046)。
  • 两组绝对风险均较低,且低于Meta分析报告的0.73%。

核心结论

  • PARPi维持治疗相比化疗 alone 的MDS/AML相对风险升高,但绝对风险未增加。

研究设计与样本

  • 英格兰回顾性队列研究,纳入11,531例接受一线化疗±PARPi维持治疗的晚期复发性卵巢癌患者,其中PARPi组1529例,化疗 alone 组10,002例。
  • 计算完成一线化疗后5年内MDS/AML的发病率,并与Meta分析结果比较。

主要发现

  • 化疗联合PARPi维持治疗组MDS/AML绝对风险为0.3%(5/1529),化疗 alone 组为0.1%(10/10,002)。
  • PARPi维持治疗相比化疗 alone 的相对风险为2.97(95%CI 1.02,8.68,p=0.046)。
  • 两组绝对风险均较低,且低于Meta分析报告的MDS/AML发生率0.73%。

临床怎么用

  • 作者认为,PARPi维持治疗相比化疗 alone 与MDS/AML相对风险小幅升高相关,但绝对风险未增加。

局限性

  • 临床试验人群高度选择,可能不能反映更广泛人群中的发病率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poly(ADP-ribose) polymerase inhibitors (PARPi) maintenance therapies are used to treat advanced ovarian cancer in first line and recurrent settings. Because of concerns about associations between PARPi therapy and secondary cancers myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), a meta-analysis of clinical trials was conducted, reporting MDS/AML incidence of 0.73 %; however, clinical trial populations are highly selective and may not reflect incidence in the wider population. METHODS: This retrospective cohort study calculated incidence of MDS/AML within five years of completing first-line chemotherapy + /- PARPi maintenance for recurrent, advanced-stage ovarian cancer. Absolute and relative risks were calculated and compared to meta-analysis. RESULTS: Of 11,531 included patients, 1529 received PARPi and 10,002 chemotherapy only. Absolute risk of MDS/AML was 0.3 % (n = 5/1529) for chemotherapy + PARPi maintenance therapy versus 0.1 % (n = 10/10,002) for chemotherapy alone. Relative risk was 2.97 (95 % CI 1.02, 8.68, p = 0.046) in patients receiving PARPi maintenance versus chemotherapy alone. DISCUSSION: Relative risk of MDS/AML was greater in patients treated with PARPi; however, absolute risk was low in both treatment groups and lower than in the meta-analysis of trials. This analysis suggests small increased relative risk of MDS/AML associated with PARPi maintenance versus chemotherapy only, but not increased absolute risk.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Steventon L, Nicum S, Chambers P, et al. Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England. Eur J Cancer. 2025. PMID: 40311508. doi:10.1016/j.ejca.2025.115472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。